Oncolytics Biotech Inc. Successfully Completes Initial Scale Up of Manufacturing Process for REOLYSIN
Oncolytics Biotech Inc. announced that it has successfully completed initial scale up of its manufacturing process for REOLYSIN(R). The process improvements and scale up to 40-litre batch size has resulted in increased total yields, which are a result of advancements in the media formulation used in the primary production of REOLYSIN(R) and in the downstream processing steps required to generate finished product. The proprietary media formulation was developed by SAFC Biosciences, of Lenexa, Kansas.
The scale up of primary production and downstream processing development was undertaken by the National Research Council Biotechnology Research Institute (NRC-BRI) located in Montreal, Canada. The process at this scale now yields at least 20,000 doses at the maximum clinical dose for intravenous use, or 60,000 doses for local use. Further increases in scale are being investigated.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.